Company intelligence / Profile preview

Fujirebio Holdings

Tokyo, Tokyo, Japan

Ownership: Private
Employees: ~1200
Development stage: Other

Overview

Fujirebio markets several globally recognized diagnostic platforms, including the LUMIPULSE G blood-based Alzheimer’s biomarker assays (RUO and FDA submission for plasma pTau 217/β-Amyloid 1-42 ratio), and was first to market CSF and plasma biomarkers for Alzheimer’s; its tests for cancer antigens (CA125, CA19-9, CA15-3) are industry standards[5].

Therapeutic areas: Infectious DiseasesOncologyNeurology
Modalities: DeviceProteinAntibodyBiologicSmall moleculeImmunoassayMolecular diagnostic assay
Industry: Protein Biomarker Diagnostics

Partnerships

Biogen (Alzheimer’s blood biomarker collaboration)Beckman Coulter (Alzheimer’s disease biomarker assay partnership)Alamar Biosciences (blood-based biomarker assay solutions via ADx NeuroSciences)

Beyond the preview

Go deeper on Fujirebio Holdings.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fujirebio Holdings.

Explore the full profile